HIV-Induced Damage of B Cells and Production of HIV Neutralizing Antibodies
| dc.contributor.author | Francesca Chiodi | * |
| dc.contributor.author | Gabriella Scarlatti | * |
| dc.date.accessioned | 2021-02-11T15:28:07Z | |
| dc.date.available | 2021-02-11T15:28:07Z | |
| dc.date.issued | 2018 | * |
| dc.date.submitted | 2018-11-16 17:17:57 | * |
| dc.identifier | 29690 | * |
| dc.identifier.issn | 16648714 | * |
| dc.identifier.uri | https://directory.doabooks.org/handle/20.500.12854/49485 | |
| dc.description.abstract | Multiple dysfunctions take place in the B cell compartment during HIV-1 infection, comprising depletion of resting memory B cells carrying serological memory to vaccines and previously met pathogens. In addition, population of B cells characterized by the expression of exhaustion markers are enlarged during HIV-1 infection. Antibodies with the capacity to neutralize a broad range of HIV-1 isolates can be detected only in a minority of infected patients, after a year or more from acute infection. An open question is whether the inability of producing neutralizing HIV-1 antibodies is somehow linked to the B cell immunopathology observed in patients. In this research topic we invited scientists to summarize the current state of knowledge on regulation and development of B cells and antibody responses during HIV-1 infection; fifteen contributions were received comprising both reviews and original articles. The articles are related to B cell dysfunctions identified in HIV-1 infected individuals, production of different types of antibodies (neutralizing versus non neutralizing, and of different isotypes) in vivo during HIV-1 infection and the biological factors which may impact on this process, clinical potential and applications of anti-HIV antibodies and how to achieve neutralizing antibody responses to HIV-1 epitopes upon vaccination. The topic has gathered articles on front-line research undertaken in the field of B cells and antibodies in HIV-1 infection. It is our hope that the collection of articles presented in this book may be useful for new and experienced scholars in the field and add a piece to the complex puzzle of knowledge needed for the development of an HIV-1 vaccine. | * |
| dc.language | English | * |
| dc.relation.ispartofseries | Frontiers Research Topics | * |
| dc.subject | R5-920 | * |
| dc.subject | RC581-607 | * |
| dc.subject.classification | thema EDItEUR::M Medicine and Nursing | en_US |
| dc.subject.other | auto-antibodies to CCR5 | * |
| dc.subject.other | BAFF | * |
| dc.subject.other | Gene Expression | * |
| dc.subject.other | clinical potential of HIV-1 antibodies | * |
| dc.subject.other | mucosal IgA responses | * |
| dc.subject.other | FcRL4 | * |
| dc.subject.other | neutralizing and non neutralizing HIV-1 antibodies | * |
| dc.subject.other | HIV-1 vaccine targets | * |
| dc.subject.other | B cells | * |
| dc.subject.other | CXCL13 | * |
| dc.subject.other | maternal HIV antibodies | * |
| dc.title | HIV-Induced Damage of B Cells and Production of HIV Neutralizing Antibodies | * |
| dc.type | book | |
| oapen.identifier.doi | 10.3389/978-2-88945-461-7 | * |
| oapen.relation.isPublishedBy | bf5ce210-e72e-4860-ba9b-c305640ff3ae | * |
| oapen.relation.isbn | 9782889454617 | * |
| oapen.pages | 171 | * |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||

